• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

溶液结构和突触分析揭示了双特异性T细胞衔接器效力的决定因素。

Solution structure and synaptic analyses reveal determinants of bispecific T cell engager potency.

作者信息

Leithner Alexander, Staufer Oskar, Mitra Tanmay, Liberta Falk, Valvo Salvatore, Kutuzov Mikhail, Dada Hannah, Spaeth Jacob, Zhou Weijie, Schiele Felix, Reindl Sophia, Nar Herbert, Hoerer Stefan, Crames Maureen, Comeau Stephen, Young David, Low Sarah, Jenkins Edward, Davis Simon J, Klenerman David, Nixon Andrew, Pefaur Noah, Wyatt David, Dushek Omer, Kasturirangan Srinath, Dustin Michael L

机构信息

The Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Roosevelt Drive, Oxford OX3 7FY, United Kingdom.

INM - Leibniz Institute for New Materials, Campus D2 2, 66117 Saarbrücken, Germany.

出版信息

Proc Natl Acad Sci U S A. 2025 Jun 3;122(22):e2425781122. doi: 10.1073/pnas.2425781122. Epub 2025 May 30.

DOI:10.1073/pnas.2425781122
PMID:40445758
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12146755/
Abstract

Bispecific T cell engagers (TcEs) link T cell receptors to tumor-associated antigens on cancer cells, forming cytotoxic immunological synapses (IS). Close membrane-to-membrane contact (≤13 nm) has been proposed as a key mechanism of TcE function. To investigate this and identify potential additional mechanisms, we compared four immunoglobulin G1-based (IgG1) TcE Formats (A-D) targeting CD3ε and Her2, designed to create varying intermembrane distances (A < B < C < D). Small-angle X-ray scattering (SAXS) and modeling of the conformational states of isolated TcEs and TcE-antigen complexes predicted close contacts (≤13 nm) for Formats A and B and far contacts (≥18 nm) for Formats C and D. In supported lipid bilayer (SLB) model interfaces, Formats A and B recruited, whereas Formats C and D repelled, CD2-CD58 interactions. Formats A and B also excluded bulky Quantum dots more effectively. SAXS also revealed that TcE-antigen complexes formed by Formats A and C were less flexible than complexes formed by Formats B and D. Functional data with Her2-expressing tumor cells showed cytotoxicity, surface marker expression, and cytokine release following the order A > B = C > D. In a minimal system for IS formation on SLBs, TcE performance followed the trend A = B = C > D. Addition of close contact requiring CD58 costimulation revealed phospholipase C-γ activation matching cytotoxicity with A > B = C > D. Our findings suggest that when adhesion is equivalent, TcE potency is determined by two parameters: contact distance and flexibility. Both the close/far-contact formation axis and the low/high flexibility axis significantly impact TcE potency, explaining the similar potency of Format B (close contact/high flexibility) and C (far contact/low flexibility).

摘要

双特异性T细胞衔接器(TcE)将T细胞受体与癌细胞上的肿瘤相关抗原相连,形成细胞毒性免疫突触(IS)。膜与膜之间的紧密接触(≤13纳米)被认为是TcE发挥功能的关键机制。为了研究这一点并确定潜在的其他机制,我们比较了四种靶向CD3ε和Her2的基于免疫球蛋白G1(IgG1)的TcE形式(A - D),其设计目的是产生不同的膜间距离(A < B < C < D)。小角X射线散射(SAXS)以及对分离的TcE和TcE - 抗原复合物构象状态的建模预测,形式A和B会形成紧密接触(≤13纳米),而形式C和D会形成远距离接触(≥18纳米)。在支持脂质双层(SLB)模型界面中,形式A和B能招募CD2 - CD58相互作用,而形式C和D则排斥这种相互作用。形式A和B也能更有效地排除体积较大的量子点。SAXS还显示,形式A和C形成的TcE - 抗原复合物比形式B和D形成的复合物灵活性更低。对表达Her2的肿瘤细胞的功能数据表明,细胞毒性、表面标志物表达和细胞因子释放遵循A > B = C > D的顺序。在SLB上形成IS的最小系统中,TcE的性能遵循A = B = C > D的趋势。添加需要紧密接触的CD58共刺激后,显示磷脂酶C - γ激活与细胞毒性相匹配,顺序为A > B = C > D。我们的研究结果表明,当黏附相当时,TcE的效力由两个参数决定:接触距离和灵活性。紧密/远距离接触形成轴和低/高灵活性轴都会显著影响TcE的效力,这解释了形式B(紧密接触/高灵活性)和C(远距离接触/低灵活性)效力相似的原因。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1039/12146755/7129d28f445a/pnas.2425781122fig05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1039/12146755/85fd34ec1525/pnas.2425781122fig01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1039/12146755/52614d21b267/pnas.2425781122fig02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1039/12146755/a1c1842f0497/pnas.2425781122fig03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1039/12146755/7be72da9c8eb/pnas.2425781122fig04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1039/12146755/7129d28f445a/pnas.2425781122fig05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1039/12146755/85fd34ec1525/pnas.2425781122fig01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1039/12146755/52614d21b267/pnas.2425781122fig02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1039/12146755/a1c1842f0497/pnas.2425781122fig03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1039/12146755/7be72da9c8eb/pnas.2425781122fig04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1039/12146755/7129d28f445a/pnas.2425781122fig05.jpg

相似文献

1
Solution structure and synaptic analyses reveal determinants of bispecific T cell engager potency.溶液结构和突触分析揭示了双特异性T细胞衔接器效力的决定因素。
Proc Natl Acad Sci U S A. 2025 Jun 3;122(22):e2425781122. doi: 10.1073/pnas.2425781122. Epub 2025 May 30.
2
One size does not fit all: navigating the multi-dimensional space to optimize T-cell engaging protein therapeutics.一刀切并不适合所有人:在多维空间中导航,以优化 T 细胞结合蛋白治疗药物。
MAbs. 2021 Jan-Dec;13(1):1871171. doi: 10.1080/19420862.2020.1871171.
3
Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy.工程化肿瘤选择性前药 T 细胞衔接双特异性抗体用于更安全的免疫治疗。
MAbs. 2024 Jan-Dec;16(1):2373325. doi: 10.1080/19420862.2024.2373325. Epub 2024 Jul 4.
4
Influence of the bispecific antibody IgG subclass on T cell redirection.双特异性抗体 IgG 亚类对 T 细胞重定向的影响。
MAbs. 2019 Aug/Sep;11(6):1012-1024. doi: 10.1080/19420862.2019.1624464. Epub 2019 Jun 26.
5
A ROR1 targeted bispecific T cell engager shows high potency in the pre-clinical model of triple negative breast cancer.一种靶向ROR1的双特异性T细胞衔接器在三阴性乳腺癌临床前模型中显示出高效能。
Breast Cancer Res. 2025 Mar 31;27(1):47. doi: 10.1186/s13058-025-02005-w.
6
Leveraging a physiologically-based quantitative translational modeling platform for designing B cell maturation antigen-targeting bispecific T cell engagers for treatment of multiple myeloma.利用基于生理学的定量转化模型平台设计针对 B 细胞成熟抗原的双特异性 T 细胞衔接器,用于治疗多发性骨髓瘤。
PLoS Comput Biol. 2022 Jul 15;18(7):e1009715. doi: 10.1371/journal.pcbi.1009715. eCollection 2022 Jul.
7
Structural and functional characterization of IgG- and non-IgG-based T-cell-engaging bispecific antibodies.IgG 基和非 IgG 基双特异性 T 细胞结合抗体的结构和功能表征。
Front Immunol. 2024 May 28;15:1376096. doi: 10.3389/fimmu.2024.1376096. eCollection 2024.
8
Characterization of a novel T cell-engaging bispecific antibody for elimination of L1CAM-positive tumors.一种用于消除L1CAM阳性肿瘤的新型T细胞衔接双特异性抗体的表征
Biomed Pharmacother. 2024 May;174:116565. doi: 10.1016/j.biopha.2024.116565. Epub 2024 Apr 11.
9
Development of T-cell engagers selective for cells co-expressing two antigens.开发选择性针对共表达两种抗原的细胞的 T 细胞衔接子。
MAbs. 2022 Jan-Dec;14(1):2115213. doi: 10.1080/19420862.2022.2115213.
10
Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release.降低 PSMAxCD3 双特异性抗体中 CD3 的亲和力可减少细胞因子释放,从而杀伤前列腺肿瘤细胞。
J Immunother Cancer. 2021 Jun;9(6). doi: 10.1136/jitc-2021-002488.

引用本文的文献

1
Innovative strategies for T cell engagers for cancer immunotherapy.用于癌症免疫治疗的T细胞衔接器的创新策略。
MAbs. 2025 Dec;17(1):2531223. doi: 10.1080/19420862.2025.2531223. Epub 2025 Jul 10.

本文引用的文献

1
Mechanical force matters in early T cell activation.机械力在早期 T 细胞激活中很重要。
Proc Natl Acad Sci U S A. 2024 Sep 10;121(37):e2404748121. doi: 10.1073/pnas.2404748121. Epub 2024 Sep 6.
2
Antibody agonists trigger immune receptor signaling through local exclusion of receptor-type protein tyrosine phosphatases.抗体激动剂通过局部排除受体型蛋白酪氨酸磷酸酶触发免疫受体信号转导。
Immunity. 2024 Feb 13;57(2):256-270.e10. doi: 10.1016/j.immuni.2024.01.007.
3
LFA-1 nanoclusters integrate TCR stimulation strength to tune T-cell cytotoxic activity.
LFA-1 纳米簇整合 TCR 刺激强度以调节 T 细胞细胞毒性活性。
Nat Commun. 2024 Jan 9;15(1):407. doi: 10.1038/s41467-024-44688-3.
4
Population dynamics of immunological synapse formation induced by bispecific T cell engagers predict clinical pharmacodynamics and treatment resistance.双特异性 T 细胞衔接器诱导的免疫突触形成的群体动力学可预测临床药效动力学和治疗抵抗性。
Elife. 2023 Jul 25;12:e83659. doi: 10.7554/eLife.83659.
5
T-cell-engaging bispecific antibodies in cancer.用于癌症治疗的T细胞接合双特异性抗体
Lancet. 2023 Jul 8;402(10396):142-158. doi: 10.1016/S0140-6736(23)00521-4. Epub 2023 Jun 1.
6
Teclistamab-cqyv: The First Bispecific T-Cell Engager Antibody for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma.替西妥单抗-cqyv:首款用于治疗复发或难治性多发性骨髓瘤患者的双特异性T细胞衔接抗体。
J Adv Pract Oncol. 2023 Mar;14(2):163-171. doi: 10.6004/jadpro.2023.14.2.7. Epub 2023 Mar 1.
7
Antigen discrimination by T cells relies on size-constrained microvillar contact.T 细胞通过抗原辨别依赖于大小受限的微绒毛接触。
Nat Commun. 2023 Mar 23;14(1):1611. doi: 10.1038/s41467-023-36855-9.
8
Inefficient exploitation of accessory receptors reduces the sensitivity of chimeric antigen receptors.辅助受体利用效率低下降低了嵌合抗原受体的敏感性。
Proc Natl Acad Sci U S A. 2023 Jan 10;120(2):e2216352120. doi: 10.1073/pnas.2216352120. Epub 2023 Jan 4.
9
Hinge disulfides in human IgG2 CD40 antibodies modulate receptor signaling by regulation of conformation and flexibility.铰链二硫键在人 IgG2 CD40 抗体中通过调节构象和柔韧性来调节受体信号转导。
Sci Immunol. 2022 Jul 15;7(73):eabm3723. doi: 10.1126/sciimmunol.abm3723. Epub 2022 Jul 8.
10
Bottom-up assembly of target-specific cytotoxic synthetic cells.靶向细胞毒性合成细胞的自下而上组装。
Biomaterials. 2022 Jun;285:121522. doi: 10.1016/j.biomaterials.2022.121522. Epub 2022 Apr 13.